No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
China National Medicines Corporation Ltd.'s (SHSE:600511) Earnings Are Not Doing Enough For Some Investors
Investors Could Be Concerned With China National Medicines' (SHSE:600511) Returns On Capital
China Merchants: Class B catalog will be released within the year + Commercial health Insurance provides additional payment for Innovative Drugs, further improving bulk purchasing and medical insurance prepayment.
The first version of the Category B directory is scheduled to be released within this year, and it is expected to be aligned with the annual adjustments of the medical insurance directory, contributing to the incremental increase of payments for Innovative Drugs.
Is China National Medicines Corporation Ltd.'s (SHSE:600511) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
China National Medicines Corporation Ltd.'s (SHSE:600511) Largest Shareholders Are Private Companies With 56% Ownership, Individual Investors Own 27%
China National Medicines (SHSE:600511) Might Be Having Difficulty Using Its Capital Effectively
